Novo Targets Teens With Wegovy As It Heads Off Lilly Mounjaro Threat
The Danish firm’s GLP-1 receptor agonist triggered significant weight loss in a Phase III trial in obese teenagers, sparking filing plans that could strengthen the product’s market share even as rival Eli Lilly mounts a threat with Mounjaro.
You may also be interested in...
Scrip has taken a look back at five of the biggest story themes in no particular order of 2022 where once again the biopharma industry had plenty on its plate.
The company has been publicly reprimanded for its training program for UK pharmacists, which the industry watchdog judged to be solely focused on increasing use of weight loss drug Saxenda
The evolution of new drugs to treat diabetes has enabled some diabetes franchises to shrug off biosimilar competition to insulins. But is some of the growth of therapies for diabetes and obesity a result of the pandemic?